免疫原性死亡在胰腺癌治疗中的应用
摘要
来，免疫原性死亡（Immunogenic Cell Death，ICD）作为一种能够激发宿主免疫反应的细胞死亡形式，在胰腺癌治
疗中展现出潜在的应用前景。本文综述了ICD的基本机制及其在胰腺癌免疫治疗中的应用。首先，本文探讨了ICD
的诱导机制，特别是DAMPs信号如钙网蛋白（CRT）、ATP及高迁移率族蛋白B1（HMGB1）的作用，并分析了其
在胰腺癌治疗中的作用潜力。接着，本文总结了ICD在胰腺癌临床前和临床研究中的应用进展。最后，本文讨论了
ICD在胰腺癌治疗中的未来发展方向。通过深入理解ICD的机制及其在胰腺癌中的应用前景，我们期望为胰腺癌的
治疗提供新的思路和策略。
关键词
全文:
PDF参考
[1]J. D. Mizrahi, R. Surana, J. W. Valle, R. T. Shroff,
Lancet 2020, 395, 2008.
[2]Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko,
O., Agostinis, P., & Vandenabeele, P. (2012). Immunogenic
cell death and DAMPs in cancer therapy. Nature reviews.
Cancer, 12(12), 860–875.
[3]杨颖，马雁冰.免疫原性细胞死亡及其在肿瘤治
疗应用中的研究进展[J].中国生物制品学杂志，2022，35
（02）：233-238.DOI:10.13200/j.cnki.cjb.003533.Krysko,
D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis,
P., & Vandenabeele, P. (2012). Immunogenic cell death and
DAMPs in cancer therapy. Nature reviews. Cancer, 12(12),
860–875.
[4]Malla R R, Kumari S, Priya G S, et al. Reactive
oxygen species of tumor microenvironment: Harnessing for
immunogenic cell death[J]. Biochimica et Biophysica Acta
(BBA)-Reviews on Cancer, 2024: 189154.
[5]Poon IK, Lucas CD, Rossi AG, Ravichandran KS.
Apoptotic cell clearance: basic biology and therapeutic
potential. Nat Rev Immunol 2014;14(3):166-180
[6]Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma
Y, Ortiz C, et al. Activation of the NLRP3 inflammasome
in dendritic cells induces IL-1beta-dependent adaptive
immunity against tumors. Nat Med. (2009) 15:1170–8.
[7]Amores-Iniesta J, Barbera-Cremades M, Martinez
CM, et al. Extracellular ATP Activates the NLRP3
inflammasome and is an early danger signal of skin allograft
rejection. Cell Rep. 2017;21:3414–3426.
[8]闻莲，何雪晴，钱一可，等.HMGB1在抗肿瘤免
疫发生中的作用[J].生命的化学，2020，40（04）：483-
489.DOI:10.13488/j.smhx.20190392.
[9]Tesniere, A.; Schlemmer, F.; Boige, V.; Kepp, O.;
Martins, I.; Ghiringhelli, F.; Aymeric, L.; Michaud, M.;
Apetoh, L.; Barault, L.; et al. Immunogenic Death of Colon
Cancer Cells Treated with Oxaliplatin. Oncogene 2010, 29,
482–491. [Google Scholar] [CrossRef] [PubMed]
[10]Ye, J.; Mills, B.N.; Zhao, T.; Han, B.J.; Murphy,
J.D.; Patel, A.P.; Johnston, C.J.; Lord, E.M.; Belt,
B.A.; Linehan, D.C.; et al. Assessing the Magnitude of
Immunogenic Cell Death Following Chemotherapy and
Irradiation Reveals a New Strategy to Treat Pancreatic
Cancer. Cancer Immunol. Res. 2020, 8, 94–107.
[11]Carbone, C.; Piro, G.; Agostini, A.; Delfino, P.;
De Sanctis, F.; Nasca, V.; Spallotta, F.; Sette, C.; Martini,
M.; Ugel, S.; et al. Intratumoral Injection of TLR9 Agonist
Promotes an Immunopermissive Microenvironment
Transition and Causes Cooperative Antitumor Activity
in Combination with Anti-PD1 in Pancreatic Cancer. J.
Immunother. Cancer 2021, 9, e002876.
[12]Lu, J.; Liu, X.; Liao, Y.-P.; Salazar, F.; Sun, B.;
Jiang, W.; Chang, C.H.; Jiang, J.; Wang, X.; Wu, A.M.;
et al. Nano-Enabled Pancreas Cancer Immunotherapy
Using Immunogenic Cell Death and Reversing
Immunosuppression. Nat. Commun. 2017, 8, 1811.
[13]Padrón, L.J.; Maurer, D.M.; O’Hara, M.H.;
O’Reilly, E.M.; Wolff, R.A.; Wainberg, Z.A.; Ko, A.H.;
Fisher, G.; Rahma, O.; Lyman, J.P.; et al. Sotigalimab and/
or Nivolumab with Chemotherapy in First-Line Metastatic
Pancreatic Cancer: Clinical and Immunologic Analyses from
the Randomized Phase 2 PRINCE Trial. Nat. Med. 2022, 28,
1167–1177.
[14]Mills BN, Qiu H, Drage MG, Chen C, Mathew JS,
Garrett-Larsen J, et al. Modulation of the Human Pancreatic
Ductal Adenocarcinoma Immune Microenvironment
by Stereotactic Body Radiotherapy. Clin Cancer Res
2022;28(1):150-162
[15]Seery, T.E.; Nangia, C.S.; McKean, H.A.; Bhar,
P.; Sender, L.S.; Reddy, S.K.; Soon-Shiong, P. Phase 2
Quilt 88 Trial of DAMP Inducers Combined with IL15
Superagonist, N-803, and Anti–PD-L1 NK Cell Therapy
More than Doubles Historical Overall Survival in Patients
with Third- to Sixth-Line Advanced Pancreatic Cancer. J.
Clin. Oncol. 2022, 40 (Suppl. 16), 4147.
Refbacks
- 当前没有refback。
